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Abstract: Drug use is a prevalent world-wide phenomenon and hepatitis virus infections are 
traditionally a major health problem among drug users (DUs). HBV and HCV, and to a 
lesser extent HAV, are easily transmitted through exposure to infected blood and body 
fluids. Viral hepatitis is not inevitable for DUs. Licensed vaccines are available for hepatitis 
A and hepatitis B. The purpose of this overview is to show some epidemiological data about 
HBV and the other blood-borne viral hepatitis among DUs and to summarize and discuss 
use of hepatitis vaccinations in this population. Successful vaccination campaigns among 
DUs are feasible and well described. We try to focus on the most significant results 
achieved in successful vaccination programs as reported in scientific literature. Vaccination 
campaigns among DUs represent a highly effective form of health education and they are 
cost-saving. 
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1. Introduction 
 
Substance abuse and consequent infections are among the most significant problems in the world. 
All drug users (DUs), not only injecting drug users (IDUs), are at increased risk for infection with at 
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least four different hepatitis viruses: hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C 
virus (HCV), and hepatitis D virus (HDV) [1, 2].  
HCV infection is the most common chronic blood-borne infection. An estimated 170 million people 
throughout the world are infected with HCV, with an estimated 5 million in Western Europe and 4 
million in the U.S  [3]. Injection of illicit drug is the most important risk factor for HCV infection in 
developed countries, with prevalence rates as high as 60% to 100%. Hepatitis C virus infection 
represents the leading cause of chronic liver disease in developed countries. The fall in the deaths from 
AIDS enhances the problem to prevent and treat HCV infection among DUs [3-10]. HCV can be easily 
transmitted through exposure to infected blood, far less so through other bodily fluids. The sharing of 
drug preparation and injection equipment can lead to rapid transmission of HCV among IDUs. Over 
the last two decades, there have been large increases in the numbers of non-injecting users of heroin in 
several countries. The sharing of equipment for intranasal use of cocaine and of pipes for smoking 
crack cocaine may also lead to transmission of these viruses [11-13]. Since there is no vaccine and no 
postexposure prophylaxis for HCV infection, its management must focus on providing primary 
prevention efforts. 
Hepatitis A is an acute, self-limiting infection of the liver caused by HAV. HAV infection occurs 
throughout the world, affecting 1.5 million people annually  [14]. Oral-fecal is the most common mode 
of transmission, with parenteral, sexual (specially by anal intercourse) and vertical transmission 
occurring less frequently. HAV infection is highly correlated with poor water sanitation facilities. 
Outbreaks have been reported among IDUs for many years and have occurred in the U.S. and Europe. 
Poor standards of living and unsafe sexual behaviors are strong risk factors leading to transmission. 
Needle sharing and blood-to-blood transmission have been suggested as possible patterns of 
transmission among IDUs [14-19].  
The World Health Organization has stated that in developed countries hepatitis A vaccination 
should be considered for DUs. Hepatitis A superimposed on chronic liver diseases is associated with 
more severe disease, including fulminant hepatic failure and a higher fatality rate [20-23]. 
HDV is a defective RNA virus that requires the presence of hepatitis B surface antigen (HBs-Ag) 
from HBV for transmission. In Europe and in the U.S., HDV infection has virtually disappeared, 
remaining confined to IDUs [33, 34]. IDUs are currently the largest source of HDV infection in the 
Western world [24-26]. 
HDV can be acquired either by co-infection with HBV or by superinfection of chronic HBs-Ag 
carriers. HDV coinfection can cause fulminant hepatitis more frequently than HBV infection alone 
while HDV supeinfection involves mostly serious chronic liver disease. Because HDV replication 
requires coinfection with HBV, immunoprophylaxis for HDV infection can be successfully achieved 
by vaccination against HBV. However, because no effective vaccine specific for HDV has been 
developed, there is currently no vaccine to protect carriers of HBs-Ag against superinfection. 
HBV is carried in blood and in other body fluids and can be transmitted through parenteral and 
sexual exposure. HBV carriers may have acute hepatitis B or chronic infection. HBV, as well as HCV, 
may be easily transmitted, not only through sharing needles, but also trough paraphernalia used in the 
preparation of the drugs. The sexual route is a very common source of infection. HBV is transmitted 
also perinatally. In the U.S., approximately 1.2 million persons have chronic HBV infection [1-3]. DUs Int. J. Environ. Res. Public Health 2009, 6          
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present a higher rate of fulminant HBV hepatitis probably related to the exposure to factors 
potentiating hepatic damage like alcohol or to HDV coinfection [27].   
In Europe, from 20% to 60% of IDUs are seropositive for HBV. The prevalence of HBV infection 
among DUs attending a methadone maintenance treatment (MMT) in Geneva was much greater 
among older DUs (80.5%) than younger ones (20.1%) [5, 28, 29]. The seroconversion rate for HBV in 
a cohort of IDUs enrolled in a syringe exchange program in Malmo was 11.7% per year (compare with 
no seroconversion among those with HIV) [30]. 
In the U.S., it is estimated that IDUs comprise 17% of all the new cases of hepatitis B. Among 
younger IDUs, HBV seroprevalence is about 25%, while for adult IDUs it is often more than 80%, 
compared with about 5% in the general U.S. population [31]. In 1999, after more than a decade of 
decline, the incidence of hepatitis B among men aged over 19 and among women aged 40 or over, has 
increased in the U.S. The most common risk factors among adults continue to be multiple sex partners, 
male with male sex, and injection drug use [32]; DUs never-injectors infected with HBV and HIV 
appear to have become infected mainly through sexual transmission, whereas former injectors appear 
to have become infected with HCV and HIV mainly through injection risk and with HBV through both 
injection and sexual risk [33, 34]; also among DUs from Rio de Janeiro (BR), HBV seems to be more 
closely associated with unsafe sex, whereas HCV is positively correlated with high risk injecting 
behaviour [35]. Prevalence for HBV has high in a large cohort of Italian DUs with no positive tests for 
syphilis in six years of follow-up [36]. 
High HBV prevalence among IDUs has been reported in several other countries with low endemic 
levels for HBV [37-39] similar to prevalence tested in IDUs living in countries highly endemic for 
HBV [36, 40, 41].  
A comprehensive and systematic review targeting HBV and other licensed vaccines 
immunogenicity in DUs has recently been published [42]. In this paper we have tried to focus on 
reports that can give concrete help and strategies for health-care providers operating in Addiction 
Treatment Clinics (ATC) to maximize adherence to hepatitis vaccination campaigns.  
 
2. Hepatitis Vaccines 
 
2.1. Hepatitis B Vaccine 
 
A vaccine against HBV was developed in 1982, and the first official recommendations for its use in 
high risk populations were published the same year  [31]. For these reasons the HBV vaccine has been 
the most studied of all vaccines in DUs. Nevertheless, only 10-25 percent of IDUs had isolated 
antibodies to hepatitis B surface antigen, consistent with vaccine-mediated immunity in U.S. and 
Europe, and outbreaks of hepatitis B among this population continue to occur [43-45]. Very recent 
studies evaluating the effectiveness of selective immunization policies in the U.S., U.K. and Spain 
underlined that vaccination levels remain low in the DU population [46-48]. Despite these 
discouraging data, good adherence to HBV vaccine has been well documented in North-Eastern Italy 
[49-53]; the best adherence to vaccination schedule was obtained when vaccine administration was 
performed directly by addiction treatment clinic (ATC) personnel [51-54]. ATCs that vaccinated less 
were also those who had worse adherence in vaccination programs [51, 52]. Int. J. Environ. Res. Public Health 2009, 6          
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HBV vaccination campaigns targeting IDUs are cost-saving  [55]. The most cost-saving strategies 
include giving the first dose to everyone at screening, administering the vaccination under the 
accelerated schedule (0, 1, 2 months) and obtaining free or highly discounted vaccine from local health 
departments; to offer HBV screening in the absence of vaccination has been proved economically 
inappropriate [55]. 
We cannot omit the possible impact of universal vaccination on DUs; according to WHO 
recommendations, universal vaccination has been currently implemented in 168 countries worldwide 
with an outstanding record of safety and efficacy. In Italy, vaccination against hepatitis B became 
mandatory for all newborns and adolescents starting from 1991, first in the world; thus, it’s of crucial 
importance to asses whether vaccinated subjects are still protected during adulthood when risk of 
infection with HBV for lifestyle can increase. A long-term immunogenicity after universal vaccination 
has been found in a large cohort of Italian healthy adolescents 10 years after vaccination. Universal 
vaccination has shown a great impact in the control of hepatitis in a former hyperendemic area in 
South Italy, but data regarding DUs is actually lacking [56-58]. Although universal vaccination could 
change the spread of HBV also among DUs, two major issues will remain: the real effectiveness of 
newborn vaccination and infection control among DUs coming from high endemicity countries. 
Suboptimal immunological responses (58%-77%) have been reported among DUs despite the 95-
99% proven in young adults from the general population [42, 59]. Dysfunction of cell-mediated 
immunity, alcohol use, polydrug abuse, multiple bacterial infections, HCV positivity and malnutrition 
are possible explanations of the lower immune response to anti-HBV vaccination in IDUs. More 
recently, smoking status has been significantly related with lower antibody response to HBV vaccine 
in patients with chronic HCV [60]. This observation is relevant because tobacco smoking and HCV 
infection are extremely prevalent among DUs and methadone maintenance patients but, despite this 
fact, substance abuse treatment programs too often ignore tobacco use [61]. Self-reported HBV 
infection status and immunization status in DUs have proved to be unreliable and the 52% claiming to 
be vaccinated were tested susceptible to HBV. As a result, some have suggested a “Don’t ask, 
vaccinate” policy for DUs [62]. 
Carriers of HCV chronic hepatitis normally respond worse than HCV negative subjects to HBV 
vaccination, and this negative influence seems to be related to HCV viral load [51, 63, 64]. In HCV 
positive subjects a larger dosage of vaccine antigen or multiple booster doses may be useful [65]. 
Substained viral response following interferon plus ribavirin treatment does not affect the antibody 
response to HBV vaccine, and vaccination during antiviral therapy is not beneficial in terms of anti-
HBs seroconversion rates [66]. HBV vaccination proved safe in chronic HCV patients. Several studies 
showed that an immunological response to HBV vaccination in patients infected with HIV was lower 
than in the normal population [42, 51, 59, 67], but a recent study has documented good seroconversion 
rates to HBV vaccine in patients with AIDS and virological response to highly active antiretroviral 
therapy (HAART) [68]. There is good evidence that individuals without detectable anti-Hbs levels for 
many years still have strong anamnestic immune responses upon in-vitro stimulation [42]. So far only 
one prospective cohort study has evaluated the long-tern benefits of vaccination in DUs [69].  
Vaccination among IDUs have been reported to be well tolerated, similar to the general population  
[51]. Pre-immunization testing may be cost effective among IDUs, where the expected prevalence of 
prior infection exceeds 30% [59, 67]. One study showed an interesting relationship between Int. J. Environ. Res. Public Health 2009, 6          
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vaccination for hepatitis B and HCV serostatus, among DUs; in this study vaccinating DUs against 
HBV may have helped to create a stronger pro-health attitude leading to a reduction in HCV risk 
behaviour [7]. The presence of the antibody to hepatitis B core antigen (anti-HBc) in the absence of 
other HBV markers is common among DUs [70, 71]. The response to HBV vaccine in isolated anti-
HBc carriers appears to vary greatly [42, 51, 63, 72]. Follow-up studies of IDUs with isolated anti-
HBc showed resistance to HBV re-infection, indicating that these patients do not require vaccination 
[70]. High Prevalence of occult HBV in IDUs has been demonstrated [73]. One study had also 
demonstrated the disappearance of HBV-DNA in a significant proportion of patients HCV-infected 
with occult HBV infection and anti-HBc-positive blood donors after HBV vaccination; but no data on 
DUs has been reported [74].  
The low coverage for HBV vaccination among DUs may be attributed to a combination of factors: 
the absence of targeted healthcare programs to provide hepatitis B vaccination for this risk group, the 
low number of health workers with the required training to carry out vaccination in ATC and the lack 
of awareness among IDUs about the risk of hepatitis [75-77]. 
Given the high risk of HBV infection, a lower post-vaccination seroprotection rate, and difficulties 
in follow-up with DUs, it is important to administer the vaccination whenever possible.  Several 
studies have shown that IDUs miss a number of opportunities for HBV vaccination [78-80]. If 
vaccination were available at many more kinds of sites, many more IDUs could receive vaccination. 
For example, methadone maintenance clinics and other drug treatment programs that require frequent 
attendance could provide vaccination services. Several studies have demonstrated a very good 
adherence to vaccine with high completion rate in these facilities [49-54]. HBV vaccine also can be 
successfully offered in on-site needle exchange services [78-80]. CDC recommends HBV vaccination 
in correctional facilities, where a high percentage of DUs are present [81]. Other venues that could 
provide immunization are emergency departments [82]. 
The goal should be to offer HBV vaccination as soon as possible after the start of illicit drug use 
and to achieve the highest possible rate of complete vaccination coverage. The inability to ensure high 
rates of completion of vaccine schedule should not preclude the initiation of vaccination. Protective 
levels of antibody develop in 30% to 55% of adults following a single dose of vaccine and in 75% 
after 2 doses; therefore, a percentage of DUs who have not completed the vaccination series are 
probably protected against HBV infection, even if at a lower rate than above reported [50]; no harm 
has been documented for receiving more than three doses. Because most hepatitis infections are 
asymptomatic, greater efforts should be made to increase the access to screening, but HBV screening 
in the absence of vaccination is not cost-effective [55, 79].  
 
2.2. Hepatitis A Vaccine 
 
Even if incidence of HAV has generally decreased in many parts of the world with improved 
hygienic conditions, many recent epidemics have been described among DUs. Approximately 40 to 
50% of IDUs in northern Europe are anti-HAV positive; but it should be noted that, in some areas, the 
HAV prevalence among IDUs does not differ from that of the general population. Cross-sectional 
serologic surveys have shown IDUs to have higher anti-HAV seroprevalence than the general U.S. 
population [83-85]. Subjects with HAV infection are viremic for as long as 30 days before the onset of Int. J. Environ. Res. Public Health 2009, 6          
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symptoms suggesting that the opportunity for parenteral transmission may be greater than previously 
suspected [86]. 
Since 1995, there have been two effective HAV vaccines on the market and the WHO has 
recommended HAV vaccination for DUs [29, 67]. Vaccination is recommended also in order to 
prevent superinfection in HCV positive subjects, which can be severe.  
A two-dose schedule is recommended for HAV vaccine, with the second dose 6-18 months after the 
first. Inactivated hepatitis A virus vaccines are highly immunogenic in the general population. 
Neutralizing antibodies are present in more than 95% of the vaccinated population one month after the 
first dose and almost all recipients have a response after the second dose [84, 87]. Similar to 
experimental observations with HBV vaccination, DUs respond weakly to vaccination compared with 
the general population; the only two studies that analyzed seroconversion among DUs reported a good 
immunogenicity only after the second dose [22, 88]. Comparable results have emerged in subjects with 
chronic liver disease [89]. The timing of the booster dose is not critical in healthy subjects, but in DUs 
the second dose is quite crucial and must be administered after a shorter time than after 6-18 month as 
normally scheduled, in order to reduce the unprotected period [31, 90].  
A lower geometric mean titer (GMT) could affect the duration of protection. There is no evidence, 
unlike with the immune response to HBV vaccine, that individuals formerly seroconverted but without 
detectable anti-HAV levels still have immune protection against HAV. However, single-dose 
immunization targeting DUs has been demonstrated to give enough protection to end HAV outbreaks 
in different settings (42). The persistence of anti-HAV titers, the duration of protection, and the 
possible need for additional vaccine booster doses in different schedules should be studied in future 
research. 
 
2.3. Hepatitis A–Hepatitis B Combined Vaccine 
 
Since 1996, in addition to the monovalent vaccines against hepatitis A and B, a combined vaccine 
containing HBs-Ag and HAV-Ag has been available. This vaccine, given in a three-dose schedule at 0, 
1, and 6 months, appears to be both as safe and as effective as monovalent vaccines [91].  
Studied for the first time in DUs, the combined vaccine proved to be safe and immunogenic [53]. 
The seroconversion rate was comparable with that for the general population; however, GMT for HAV 
and HBV, as documented with the other vaccines among DUs, proved lower than those reported in the 
literature. One interesting item emerging from this study was that the anti-HBV and anti-HAV 
responses were much higher than in the case of monovalent vaccines in two cohorts of DUs. It is 
possible that the combined vaccine could have an adjuvant effect for both components (mutual 
immune reinforcement), as reported for the general population. This effect would be particularly useful 
in DUs because the peak antibody titre is relevant in providing a longer protection, specially for HAV. 
Even if further studies are required, this study suggests that IDUs who are HAV/HBV-negative could 
be better vaccinated with the combined vaccine than with monovalent ones [22, 50, 53]. 
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3. Discussion 
 
All of Authors of this paper have been working as staff members in vaccination campaigns among 
DUs. We have tried to point out, through summarizing published data and, also, from our own 
experience, the essential take-home messages for safe, successful vaccination programs in hard-to-
reach populations.  
Remember that: 
•  Good addiction therapy means good adherence to vaccination programs. Multi-disciplinary 
management models have proved to be effective, among DUs, in vaccinating and in treating 
HCV chronic hepatitis as well [92].  
•  Vaccination programs with minor drop-out turn out to be those administrated directly by ATC 
personnel. In our experience this is the first of all issues.  
•  ATCs which vaccinate less are also those that have worse adherence in vaccination programs. 
•  HBV screening in the absence of free access to vaccination is a wasted opportunity. 
•  HBV vaccine boosters are no longer made to patients who have documentated seroconversion 
even if anti-HBs titre get lost. This is not true for HAV vaccine.  
•  Main issue is no longer to quantify anti-HBs titre, but if there is any seroconversion or not. On 
that purpose it is important to follow the vaccine schedule (0, 1, 6 months or 0, 1, 2 months) 
with a serum control at the end; a booster dose in lack of response can be determinant. No harm 
has been reported from receiving more than three doses. 
•  Short schedule (0, 1, 2 months) reduces drop-out; it’s cost-saving even if it is proved to be less 
immunogenic comparing with the usual one (0, 1, 6 months) . 
•  DUs are less responsive to hepatitis vaccines than the general population both in 
immunogenicity and reactogenicity.  
•  IDUs with isolated anti-HBc they showed resistance to HBV re-infection in follow-up studies 
and, in our opinion, these patients do not require HBV vaccination. 
•  Self-reported HBV infection status and immunization status in DUs have proven to be 
unreliable. However, even if some clinicians adopt a “Don’t ask, vaccinate” policy, we believe 
that good data collecting can be easier, less expensive and more effective among DUs in 
methadone/buprenorphine maintenance programs.  
•  It should be remembered that HIV positive subjects seroconverted to anti-HBs less than HIV 
negative but also that patients with AIDS and virological response to HAART have a good 
immunological response to HBV vaccination.  
•  Carriers of HCV chronic hepatitis normally respond worse than HCV negative to HBV 
vaccination; they deserve a more careful follow-up. 
•  Scheduling for HAV vaccination has been designed mainly for travelers who need fast 
protection; when evaluated among DUs it proved to be far less immunogenic and reactogenic 
than in the general population. Our opinion is that a booster dose is needed soon after the first 
dose.  
•  A combined vaccine (HAV and HBV) can give better results than a monovalent one both in 
immunogenicity and seroconversion rate. This fact could be relevant for a longer protection, 
specially against HAV.  Int. J. Environ. Res. Public Health 2009, 6          
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•  Vaccinating DUs against hepatitis may help to create a stronger pro-health attitude leading to a 
reduction in HCV and HIV risk behavior.  
•  Preventing HBV and HAV among DUs can really limit the spread in the general population 
and it has been demonstrated to be cost-saving. 
 
4. Conclusions 
 
The literature briefly reviewed in this paper suggests that substance abuse and blood-borne hepatitis 
are highly prevalent in the world today, with serious morbidity and mortality complications. DUs are 
at high risk for vaccine-preventable infections but generally have the lowest vaccination coverage 
rates. The health consequences extend beyond individual DUs to their sexual partners, households and 
communities as a whole, until universal vaccination reaches the high-risk age. Successful vaccination 
campaigns among DUs have been demonstrated to be feasible and effective.  
Further studies are required to clarify situations correlated with a lower immune response to 
vaccinations in DUs and for tailored vaccination schedules giving better immune responses. Data on 
HAV vaccination are still scarce. The ability of DUs to improve their health and reduce the risk of 
acquiring or transmitting hepatitis is directly related to the quality of the prevention and care services 
they receive. In future we hope that vaccines for HIV and HCV will be developed. It would be 
paradoxical indeed if, at some time, coverage of DUs will be stopped for lack of experience in 
performing vaccine programs among this vulnerable group.  
Improving HAV and HBV vaccination programs for DUs represents a highly effective and cost-
saving form of health action.   
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